---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036226"
form_type: "8-K/A"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:12:10.372309+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q2 revenue down 30% to $56M, launches RIF cutting 35% of workforce for >$85M annual savings

## Summary
- Q2 total revenue $56M vs $81M YoY; Cell Engineering $36M (-20%), Biosecurity $20M (41% gross margin).
- Loss from ops $(223)M incl. $72M restructuring costs; Adjusted EBITDA $(99)M vs $(80M) prior year.
- Reduction in force impacting 35% of workforce, expected to yield >$85M annualized savings by mid-2025.
- Restructuring costs estimated $18-22M in Cell Engineering; facilities consolidation underway.
- FY 2024 outlook reaffirmed: total revenue $170-190M, Cell Engineering $120-140M, Biosecurity ≥$50M.

## SEC filing metadata
- accession: 0001628280-24-036226
- form_type: 8-K/A
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/0001628280-24-036226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/dna-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036226
- JSON: https://secwatch.observer/filing/0001628280-24-036226.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036226.txt

## Key facts
- Restructurings & Charges
  Ginkgo Bioworks Holdings, Inc. announced a restructuring with charges of $18.0 million to $22.0 million affecting Cell Engineering segment (35% of the workforce).
  - Type: restructuring
  - Charge: $18.0 million to $22.0 million
  - Affected area: Cell Engineering segment
  - Headcount: 35% of the workforce
  source text: The Company currently estimates the costs for the reduction in force to range from $18.0 million to $22.0 million primarily in the Cell Engineering segment and consist of one-time cash severance and related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/0001628280-24-036226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.